Psoriatic Arthritis

Does JAKi carry higher late MACE/VTE risk in PsA? TriNetX: no difference at 0-2 yrs, but at 2-5 yrs TNFi and IL-17i had HRs of 0.50 and 0.45 vs JAKi. Retrospective, small JAKi group, residual confounding possible. A#2304 @RheumNow #ACR26 https://t.co/wmpgay1ayF

https://x.com/JihaRheum/status/2120187728503386183/photo/1

TOGETHER PsO and PsA pooled (n=545): at week 36, adding tirzepatide to ixekizumab increased PASI 100 by 11.1% and PASI 90 by 12.6%. Key finding: the combination also improved HbA1c, triglycerides and blood pressure compared with ixekizumab alone. @rheumnow #ACR26 Abstract#2298

Can a structured program get PsA patients off prednisolone? A 3-step model: 1. GC education for patients and physicians 1. Individualized 12wk taper 3. Feedback line for adherence problems 26/46 (56.5%) stopped GC by 3mo. A#2303 @RheumNow #ACR26

Does apremilast work in early PsA? Pooled data from 7 trials (n=943, disease duration ≤2 years) show significant wk 16 gains in ACR response, cDAPSA, enthesitis and PROs, but not dactylitis. What of with longer-duration disease? A#2293 @RheumNow #ACR26 https://t.co/eYPSu0x0H2

https://x.com/JihaRheum/status/2120181436875432414/photo/1

No clear 12mo persistence diff b/w IL-17Ai (n=385) and IL-23i (n=233) in PsA (CorEvitas) Class-level 56.2% vs 57.4% (HR 1.06, 0.78-1.46) Drug-level 48.9% vs 54.1% (HR 1.19, 0.88-1.60). IL-17Ai group had more prior b/tsDMARD use (60.5% vs 48.9%). A#2288 @RheumNow #ACR26 https://t.co/DmSzdSruKu

https://x.com/JihaRheum/status/2120178920079471104/photo/1

Medicare should improve access, but in cohort of 176 pts with IA, including PsA, 50% d/c'ed b/tsDMARD after Medicare enrollment, and cost or access factors drove 45% of therapy changes. Does prior insurance type affects disruption ? Abstract #2714 @RheumNow #ACR26 https://t.co/LTbyVQi99v

https://x.com/JihaRheum/status/2120177661956014185/photo/1

Kishimoto et al: ICONIC-PsA 1 tested oral IL-23R peptide icotrokinra in biologic-naive PsA. Week 16 ACR20: 58% with 200 mg vs 41% placebo (p=0.002). Oral targeted therapy could expand PsA choices. @rheumnow #ACR2026 Abstract#LB12

Swiss SCQM registry: 63.6% of 2,087 PsA patients had overweight or obesity, against 31% overweight and 12% obese in the general population. Key finding: higher BMI was associated with higher disease activity, cardiometabolic comorbidity and depression. @rheumnow #ACR26

US health records, 19.9 million patients, 2018 to 2024: 81.8% of people with PsA had overweight or obesity vs 73.4% without PsA. Key finding: obesity was associated with 1.8 times the hazard of incident PsA. @rheumnow #ACR26 Abstract#2015

Ab#2804 #ACR26 @RheumNow BE BOLD: Bimekiz v Risankiz in PsA, 24w H2H P3B W16 (primary endpt): ACR50: BKZ 49% v 38% RZB, p=.006, W24: 56% v 44% MDA, ACR50+PASI100 NOT signif PASI100: BKZ earlier, equal later BKZ - better for jts, earlier skin but equal later, more Candida #ACRBest https://t.co/q6g6zQMutY

IL17Ai vs IL23i in PsA, US registry, 385 vs 233 patients: class persistence at 12 months 56.2% vs 57.4% (HR 1.06), drug persistence 48.9% vs 54.1% (HR 1.19). Key finding: persistence did not differ significantly between the two classes. @rheumnow #ACR26 Abstract#2288

In this retrospective cohort study of axSpA/PsA pts, 41.7% had 1st line retention, tx cycling (41.4%) & mech switch (17%) Tx retention longer in axSpA than PsA Reasons for switching? AEs, secondary failure, primary failure. @RheumNow #ACR26 Abs2300 https://t.co/BImZw86wQo

https://x.com/RHEUMarampa/status/2120165330425401799/photo/1

Maybe a slightly gentler incline than bimekizumab & maybe a bit closer to guselkumab, but the new oral IL-23i icotrokinra works in PsA. It's great to have a potential oral PsA option that is very safe but also has the required modern standard for skin ABSTLB12 #ACR26 @RheumNow https://t.co/Duofo3ZzZ7

https://x.com/drdavidliew/status/2120136389912035633/photo/1

Deucravacitinib in PsA with axial involvement, POETYK PsA 1 and 2 (about 15% of patients): BASDAI and ASDAS improved more than placebo at week 16 in PsA 2, but not significantly in PsA 1. Key finding: axial measures improved through week 52 in both trials; the authors describe

Article

Biologic Dosing and Obesity

Jiha Lee, MD Nov 10, 2026

A 46-year-old with psoriatic arthritis and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Switch class, optimize methotrexate, or ask whether the dose itself is too low? Stephen Balevic, MD, PhD, discusses this question in "

RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by UCB. All coverage content is independently selected by RheumNow and its faculty.

Article

Are GLP-1s Doing More Than Shrinking Waistlines in PsA?

Audrey Gibson, MsPAS, PA-C Nov 09, 2026

We have spent years telling patients with PsA that weight loss may improve symptoms and reduce cardiometabolic risk. A new ACR 2026 abstract asks the more provocative question: could GLP-1–based therapy influence PsA outcomes even after accounting for the change on the scale?

RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by UCB. All content is independently selected by RheumNow and its faculty.

Article

PsA: Are new IL-23 agents impactful in today’s treatment landscape?

Brian Jaros, MD Nov 09, 2026

IL-23 therapies are among the most efficacious and safest treatment options for patients with skin psoriasis. The enthusiasm for IL-23 agents for PsA is perhaps more tempered; while efficacy has been demonstrated for peripheral joint disease, there is concern that these agents are not effective

LLM extraction from 488 PsA records (Columbia): 42.6% met full CASPAR criteria and 43.2% had inflammatory features without full CASPAR. Key finding: CASPAR features were extracted at scale, while cDAPSA was documented in 4.9% of records. @rheumnow #ACR26 Abstract#1348

Who stays on PsA Therapy? British prospective PsA registry: 815 pt on b/tDMARD Factors affecting drug d/c: - PDE-4 use - higher BMI - enthesitis - lower physician global assessment - polysymptomatic stress Protective: - concomittent csDMARD use #Abst1324 @RheumNow #ACR26

Characterizing nociplastic pain in axSpA -Cohort study to estimate prevalence of nociplastic pain in a axSpA and its impact on symptom burden, disease activity and qualitative sensory testing (QST). -83 pts, half were women with axSpA. -Pts completed fibromyalgia survey

The PsA Weight-Loss Treatment Gap: Are We Missing the Bigger Picture? Among the groundbreaking clinical trials and new treatment strategies, one of the most important stories may be about something we aren't doing enough of: addressing obesity and cardiometabolic risk in our https://t.co/ivEm4Dg4QZ

Kaka et al: In a national PsA analysis, 76.7% met GLP-1 eligibility criteria, yet none reported treatment in the analyzed sample. A striking gap between metabolic risk and care. An important call for action. @rheumnow #ACR2026 #ACRBest Abstract#1343 https://t.co/RP1d8PEBwe

Rex et al: In PsA, rheumatologists estimated GLP-1 use at 14%, while 37% were considered strong candidates. The treatment gap may be one of the biggest stories. Who should take the lead in metabolic care? @rheumnow #ACR2026 #ACRBest Abstract#1315 https://t.co/nTPf2MhKN5

https://x.com/Gibson_RheumPAC/status/2119844969854726570/photo/1

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact

Nov 01, 2026

In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions

Read Post